NURTURE: Pre- vs. post-symptomatic treatment

Pre-symptomatic SPINRAZA® treatment: Significant benefit vs treating after symptom onset1

  • Patients treated pre-symptomatically in NURTURE were compared to patients treated after symptom onset in ENDEAR (a Phase III, randomised, sham-controlled trial in infantile-onset (Type I) SMA)1
  • The greatest improvements in HINE Section 2 total motor milestone scores were observed in infants treated with SPINRAZA® before symptom onset1

Change in HINE-2 motor milestone score over time (integrated analysis)*1

Scheme
Scheme

*NURTURE study interim analysis data cutoff date: May 15 2018; ENDEAR-SHINE integrated analysis data cutoff date: June 30 2017. CS3A end-of-study data for the cohort of infants with 2 SMN2 copies. ENDEAR participants with 2 SMN2 copies in the intention-to-treat population. ENDEAR data were windowed into intervals based on time from baseline. For each study, n≥5 are plotted.1

Banner
Banner

Stock image (not a real patient).

Visit Together in SMA for in-depth disease information and support services

References:
1. SPINRAZA® Summary of Product Characteristics.